Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1506 participants.

Also called NCT02866175

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,506 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02866175
  • EudraCT 2016-002683-14
Other papers using this trial's data
  • Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis Clinical research in cardiology : official journal of the German Cardiac Society, 2021-06 DOI, PubMed 33098470, PMC8166657 In the PMC Open Access subset under CC BY.
  • Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial Lancet (London, England), 2019-10-12 DOI, PubMed 31492505

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, South Korea, Spain, Switzerland, Taiwan, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02866175. Randomized; no masking; primary purpose treatment. Start 2017-02-24 (actual); primary completion 2019-06-06 (actual). Results posted on 2020-05-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Acronym
ENTRUST-AF-PCI
Intervention (Drug)
Edoxaban
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Prasugrel
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Vitamin K antagonist
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct02866175
Content hash
46f5586fc86a31689d4896159a711c4a1ab7c65468fa9d013e5439a243a6bfe9